Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01242930 · ClinicalTrials.gov registry record · Phase 2
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 2
- Study locations
NCT01242930 is a Phase 2 study of Multiple Myeloma that has completed, run by Geron Corporation. The registered enrollment target is 13 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01242930, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open label Phase II study to determine the rate of improvement in response of patients with previously treated multiple myeloma to imetelstat alone or in combination with lenalidomide maintenance therapy. This study will include multiple myeloma patients who either have achieved disease stabilization or who have achieved at least a partial response (PR) but failed to achieve a complete response (CR) after cytoreductive therapy for multiple myeloma; ie, have detectable but non-progressing disease and will most likely relapse.
Conditions Studied
Interventions
- DRUG Imetelstat (7.5 mg/kg)
- DRUG lenalidomide standard of care
- DRUG Imetelstat (9.4 mg/kg)
Study Locations (2)
Maryland
- University of Maryland Medical Center - M & S Greenebaum Cancer Center - Baltimore
- Sidney Kimmel Cancer Center Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01242930
The ClinicalTrials.gov registry entry for NCT01242930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Imetelstat (7.5 mg/kg) is the first listed.
NCT01242930 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01242930 about?
NCT01242930 is a clinical study titled "Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma". This is an open label Phase II study to determine the rate of improvement in response of patients with previously treated multiple myeloma to imetelstat alone or in combination with lenalidomide maintenance therapy. This study will include multiple myeloma patients who either have achieved disease s...
What is the current status of trial NCT01242930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2010-11. Estimated completion is 2014-11.
What conditions does trial NCT01242930 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01242930?
The interventions under investigation include: Imetelstat (7.5 mg/kg) (DRUG), lenalidomide standard of care (DRUG), Imetelstat (9.4 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT01242930?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01242930 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.